Novartis agreed to acquire Excellergy for up to $2 billion, adding a next-generation anti-IgE platform to bolster its allergy pipeline. Excellergy’s lead candidate, Exl-111, is in Phase 1 with a receptor-focused approach designed to downregulate FcεRIα signaling and suppress IgE without triggering mast-cell activation.